BRNS
Barinthus Biotherapeutics Plc
NASDAQ · Healthcare · Biotechnology · GB
$0.74
−2.49%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.74
From 52W high−53.16%
Volume0.00
Market cap$30.23M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.74
From 52W high
−53.16%
Volume
0.00
Market cap
$30.23M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
P/E (TTM)
—
RSI (14)
60.2
MomentumView details →
1D Return
−2.49%
YTD Return
+5.70%
SummaryUpdated Jun 1, 2026
Barinthus Biotherapeutics plc (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Harwell, United Kingdom. Originally known as Vaccitech plc, the company rebranded to Barinthus Biotherapeutics in November 2023. The company went public in April 2021 and focuses on developing novel T cell immunotherapeutics designed to guide the immune system in treating chronic infectious diseases, autoimmune conditions, and cancer.
Similar companies
Latest newsMore news →
Beacon Topco, Inc. amended its merger agreement with Barinthus Biotherapeutics plc, Cdog Merger Sub, Inc. and Clywedog Therapeutics, Inc., setting the closing date and the 'End Date' at October 31, 2026.26d agoBarinthus Biotherapeutics plc transferred its listing from NASDAQ to another exchange, as disclosed in an 8-K filing on August 24, 2026.56d ago